First line Treatment of EGFR m+: Benefit from First Generation TKI vs. Chemo

Date 28 October 2016
Event ESMO Advanced Course on Metastatic EGFR-Mutant NSCLC 2016
Session Session 1 The already long journey of EGFR TKI
Topics Cytotoxic agents
Therapy
Biological therapy
Presenter T. Mok, HK